Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
Commentary|Articles|November 29, 2024
Gift Guide for Psychiatric Readers
Author(s)Megan McSweeney
Looking to buy books as gifts this year? We've got you covered.
Advertisement
Advertisement
Related to this article
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Brain Trust: Bessel van der Kolk, MD, on Complex PTSD, Attachment, and the Limits of Pharmacotherapy
3
Podcast: Campus Naloxone Access and Destigmatizing Substance Use Disorders
4
Artificial Intelligence in Psychiatric Clinical Trials: Opportunities and Limitations
5